VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Breast 2020 | Personalizing immunotherapy beyond PDL1 expression

Marleen Kok • 14 May 2020
ESMO Breast 2020
Breast Cancer Antibodies Atezolizumab Durvalumab Nab-paclitaxel Nivolumab Pembrolizumab
I-SPY IMpassion130 KEYNOTE-012

Marleen Kok, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses personalizing immunotherapy beyond PD-L1 expression. Specifically discussed is the IMpassion130 trial (NCT02425891), neoadjuvant data and tumor mutational burden. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Marleen Kok

2:36
TILS related to BRCA-like status
Marleen Kok • 12 May 2020
2:54
Neoadjuvant chemoimmunotherapy: KEYNOTE-522, I-SPY & more
Marleen Kok • 7 May 2020

Related Videos

8:01
Immune oncology in breast cancer: KEYNOTE-086, NCI 10013, & AIPAC
Sangeetha Reddy • 16 Dec 2020
2:36
Tailoring medicine in breast cancer
Erika Hamilton • 15 Dec 2020
2:09
MARIO-3: eganelisib in TNBC
Erika Hamilton • 15 Dec 2020
1:14
HER2CLIMB: outcomes by hormone receptor status
Erika Hamilton • 15 Dec 2020
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals